Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics
- Psychedelic drugs are on cusp of entering mainstream treatment for mental illness
- Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research
- Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra
A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://nnw.fm/BIvoD). Another strong indicator of the future of psychedelics is the exciting partnership just announced by Cybin (NEO: CYBN) (NYSE American: CYBN). The psychedelic therapeutics company is joining forces with the Chopra Foundation to increase education and awareness of the potential use of psychedelics in supporting well-being and mental health (https://nnw.fm/eKdB3).
“After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction,” the New York Times reported. “The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides.”
The article pointed to recent research by Rick Doblin, a pioneering psychedelics researcher, as evidence of that trajectory. “Dr. Doblin’s quest to win mainstream acceptance of psychedelics took a significant leap forward . . . when the journal ‘Nature Medicine’ published the results of his lab’s study on MDMA, the club drug popularly known as ecstasy and molly,” the article stated. “The study, the first phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder.
“The results, coming weeks after a ‘New England Journal of Medicine’ study that highlighted the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms, have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine,” the article continued. “They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later.”
This trend is almost certainly behind the new partnership between Cybin and the Chopra Foundation. Cybin has emerged as a leader in the psychedelic space, producing solid research indicating that psychedelic-assisted therapy can potentially improve the quality of life for people suffering with mental illnesses, including major depressive disorder, alcohol use disorder and anxiety disorders. The new partnership calls for the Chopra Foundation and Cybin to collaborate on efforts aimed to support education and awareness about groundbreaking research to harness the potential of psychedelic therapies in mental health.
“The need for new and more effective treatments across the mental health spectrum is more urgent today than ever,” said Chopra Foundation founder, director and board chair Dr. Deepak Chopra. “Through our NeverAlone movement, we aim to combine forces with the best and brightest across businesses, policymakers, mental health professionals and others — all with the goal of building awareness, advancing scientific research and creating a global community to ensure widespread access to well-being resources. As the number of companies pursuing psychedelic-based therapies continues to grow, the foundation is particularly excited about partnering with Cybin based on its commitment to global well-being and mental health.”
Noting that Cybin is one of the only companies that may truly address the needs of patients and providers, Chopra pointed out that “Cybin has cultivated a leadership position in this space based on their proprietary scientific approach that delivers the healing properties of classic psychedelics while reducing variable side effects that have prevented these natural compounds from becoming therapies in the past. . . . Their vision for improving the landscape of mental illness perfectly aligns with our goals, and we look forward to a productive partnership to further both of our missions.”
Cybin CEO Doug Drysdale stated that the company is honored to partner with the Chopra Foundation and be part of the NeverAlone Initiative. “Much is understood about psychedelics, as they have been studied in academia for decades, but there is still much investigative work to be done,” he said. “At Cybin, we are using medicinal chemistry and drug-delivery technologies to build on existing clinical data and improve the patient experience by overcoming the limitations of current treatments for mental illness. We share the foundation’s pioneering spirit with regard to mental health and well-being and its goal of ensuring accessibility to much-needed treatment options to those in need.”
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Psychedelic drugs are on cusp of entering mainstream treatment for mental illness
- Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research
- Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra
A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://nnw.fm/BIvoD). Another strong indicator of the future of psychedelics is the exciting partnership just announced by Cybin (NEO: CYBN) (NYSE American: CYBN). The psychedelic therapeutics company is joining forces with the Chopra Foundation to increase education and awareness of the potential use of psychedelics in supporting well-being and mental health (https://nnw.fm/eKdB3).
“After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction,” the New York Times reported. “The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides.”
The article pointed to recent research by Rick Doblin, a pioneering psychedelics researcher, as evidence of that trajectory. “Dr. Doblin’s quest to win mainstream acceptance of psychedelics took a significant leap forward . . . when the journal ‘Nature Medicine’ published the results of his lab’s study on MDMA, the club drug popularly known as ecstasy and molly,” the article stated. “The study, the first phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder.
“The results, coming weeks after a ‘New England Journal of Medicine’ study that highlighted the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms, have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine,” the article continued. “They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later.”
This trend is almost certainly behind the new partnership between Cybin and the Chopra Foundation. Cybin has emerged as a leader in the psychedelic space, producing solid research indicating that psychedelic-assisted therapy can potentially improve the quality of life for people suffering with mental illnesses, including major depressive disorder, alcohol use disorder and anxiety disorders. The new partnership calls for the Chopra Foundation and Cybin to collaborate on efforts aimed to support education and awareness about groundbreaking research to harness the potential of psychedelic therapies in mental health.
“The need for new and more effective treatments across the mental health spectrum is more urgent today than ever,” said Chopra Foundation founder, director and board chair Dr. Deepak Chopra. “Through our NeverAlone movement, we aim to combine forces with the best and brightest across businesses, policymakers, mental health professionals and others — all with the goal of building awareness, advancing scientific research and creating a global community to ensure widespread access to well-being resources. As the number of companies pursuing psychedelic-based therapies continues to grow, the foundation is particularly excited about partnering with Cybin based on its commitment to global well-being and mental health.”
Noting that Cybin is one of the only companies that may truly address the needs of patients and providers, Chopra pointed out that “Cybin has cultivated a leadership position in this space based on their proprietary scientific approach that delivers the healing properties of classic psychedelics while reducing variable side effects that have prevented these natural compounds from becoming therapies in the past. . . . Their vision for improving the landscape of mental illness perfectly aligns with our goals, and we look forward to a productive partnership to further both of our missions.”
Cybin CEO Doug Drysdale stated that the company is honored to partner with the Chopra Foundation and be part of the NeverAlone Initiative. “Much is understood about psychedelics, as they have been studied in academia for decades, but there is still much investigative work to be done,” he said. “At Cybin, we are using medicinal chemistry and drug-delivery technologies to build on existing clinical data and improve the patient experience by overcoming the limitations of current treatments for mental illness. We share the foundation’s pioneering spirit with regard to mental health and well-being and its goal of ensuring accessibility to much-needed treatment options to those in need.”
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
